Volume 23 - Issue 12 - December 2015
Department
Research in Review
12/21/2015
Alexander K. Leung, MD, and Benjamin Barankin, MD
A 13-year-old boy with a history of chronic atopic dermatitis, which had mainly affected the antecubital and popliteal areas, presented with a diffuse papular eruption in the lower abdomen that had persisted for approximately 9 months.
A 13-year-old boy with a history of chronic atopic dermatitis, which had mainly affected the antecubital and popliteal areas, presented with a diffuse papular eruption in the lower abdomen that had persisted for approximately 9 months.
A 13-year-old boy with a...
12/21/2015
The Dermatologist
Derm Dx
12/18/2015
A 51-year-old Caucasian man presented with asymptomatic lesions on his breasts of several years’ duration. Cutaneous examination revealed individual and confluent white-yellow dermal papules and plaques involving the areola and nipple...
A 51-year-old Caucasian man presented with asymptomatic lesions on his breasts of several years’ duration. Cutaneous examination revealed individual and confluent white-yellow dermal papules and plaques involving the areola and nipple...
A 51-year-old Caucasian man...
12/18/2015
The Dermatologist
Column
Therapeutic Review
12/21/2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy.
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy.
In a study published...
12/21/2015
The Dermatologist
Therapeutic Review
12/21/2015
The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology.
The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology.
The prevalence of non-alcoholic...
12/21/2015
The Dermatologist
Spotlight
12/21/2015
Dr. Ochoa is an associate professor of dermatology at the Keck School of Medicine University of Southern California.
Dr. Ochoa is an associate professor of dermatology at the Keck School of Medicine University of Southern California.
Dr. Ochoa is an associate...
12/21/2015
The Dermatologist
News
News
12/21/2015
Apremilast, an oral phosphodiesterase-4 inhibitor, can reduce the severity of nail and scalp psoriasis.
Apremilast, an oral phosphodiesterase-4 inhibitor, can reduce the severity of nail and scalp psoriasis.
Apremilast, an oral...
12/21/2015
The Dermatologist
News
12/18/2015
FDA announced two proposed rules preventing the use of sunlamp products (indoor tanning beds) by minors and reducing the risk of using these devices for adults.
FDA announced two proposed rules preventing the use of sunlamp products (indoor tanning beds) by minors and reducing the risk of using these devices for adults.
FDA announced two proposed rules...
12/18/2015
The Dermatologist
12/18/2015
Alessia D'
anna, Assistant Editor
A look at the biggest advances of 2015 that impact the field of dermatology and patient care.
A look at the biggest advances of 2015 that impact the field of dermatology and patient care.
A look at the biggest advances...
12/18/2015
The Dermatologist
12/18/2015
In this supplement, we take stock of where we are now with respect to psoriasis treatment
In this supplement, we take stock of where we are now with respect to psoriasis treatment
In this supplement, we take...
12/18/2015
The Dermatologist
Feature
NPF Endorsed Features
12/18/2015
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque...
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque...
Dermira, Inc., a specialty...
12/18/2015
The Dermatologist
